Grifols SA
MAD:GRF
Grifols SA
MAD:GRF
Price:
10.93
EUR
-0.23%
Market Closed
Market Cap:
€7.4B
Relative Value
The Relative Value of one
GRF
stock under the Base Case scenario is
26.19
EUR.
Compared to the current market price of 10.93 EUR,
Grifols SA
is
Undervalued by 58%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GRF
Relative Value
Base Case
26.19
EUR
Undervaluation 58%
Multiples Across Competitors
GRF Competitors Multiples
Grifols SA Competitors
Grifols SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Grifols SA
MAD:GRF
|
7.5B EUR | 1 | 20.2 | 7.4 | 11.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.5B USD | 6.7 | 170.6 | 16.5 | 23.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.1B USD | 5.1 | 26.3 | 18.8 | 18.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.9B USD | 6.2 | 22.2 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD | 10.1 | 32.2 | 23.7 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.1B USD | 5.6 | 17.8 | 15 | 17.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.6B AUD | 3.9 | 20.4 | 13.6 | 17 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR | 14.5 | 34.2 | 58.4 | 60.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
